Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $48.3333.

Several equities research analysts recently commented on RAPP shares. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a report on Thursday, January 8th. BTIG Research reissued a “buy” rating and issued a $47.00 price objective on shares of Rapport Therapeutics in a research note on Monday, December 8th. The Goldman Sachs Group restated a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Citizens Jmp lifted their target price on Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Wells Fargo & Company set a $51.00 price target on shares of Rapport Therapeutics in a research report on Friday, December 19th.

Rapport Therapeutics Stock Down 3.5%

RAPP stock opened at $26.93 on Monday. The company has a 50-day simple moving average of $28.59 and a 200 day simple moving average of $23.70. The company has a market capitalization of $1.28 billion, a P/E ratio of -9.94 and a beta of 1.63. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Thursday, November 6th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.06. Equities analysts anticipate that Rapport Therapeutics will post -3.65 EPS for the current year.

Insider Buying and Selling at Rapport Therapeutics

In other Rapport Therapeutics news, insider David Bredt sold 8,500 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $30.02, for a total transaction of $255,170.00. Following the completion of the sale, the insider directly owned 392,642 shares in the company, valued at approximately $11,787,112.84. This trade represents a 2.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Abraham Ceesay sold 5,833 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $29.64, for a total value of $172,890.12. Following the completion of the transaction, the chief executive officer owned 567,913 shares in the company, valued at $16,832,941.32. This represents a 1.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 67,655 shares of company stock worth $1,863,705 over the last three months. 13.57% of the stock is owned by insiders.

Institutional Trading of Rapport Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio raised its position in shares of Rapport Therapeutics by 23.5% during the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after acquiring an additional 400 shares during the last quarter. Creative Planning grew its stake in shares of Rapport Therapeutics by 12.8% during the third quarter. Creative Planning now owns 11,959 shares of the company’s stock worth $355,000 after purchasing an additional 1,357 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Rapport Therapeutics during the third quarter worth $43,000. Two Sigma Investments LP increased its holdings in Rapport Therapeutics by 8.9% in the third quarter. Two Sigma Investments LP now owns 21,500 shares of the company’s stock valued at $639,000 after purchasing an additional 1,757 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in Rapport Therapeutics by 54.4% in the fourth quarter. SG Americas Securities LLC now owns 9,673 shares of the company’s stock valued at $293,000 after buying an additional 3,408 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.